← FDA DRUG APPROVALS

FDA ANDA · ANDA076021

TERAZOSIN HYDROCHLORIDE

Sponsor: RANBAXY LABS LTD

APPLICATION
ANDA076021
TYPE
ANDA
ORIGINAL APPROVAL
2002-08-22
LATEST ACTION
2002-08-22
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

TERAZOSIN HYDROCHLORIDEDiscontinued
TERAZOSIN HYDROCHLORIDE EQ 2MG BASE · CAPSULE · ORAL
TERAZOSIN HYDROCHLORIDEDiscontinued
TERAZOSIN HYDROCHLORIDE EQ 5MG BASE · CAPSULE · ORAL
TERAZOSIN HYDROCHLORIDEDiscontinued
TERAZOSIN HYDROCHLORIDE EQ 1MG BASE · CAPSULE · ORAL
TERAZOSIN HYDROCHLORIDEDiscontinued
TERAZOSIN HYDROCHLORIDE EQ 10MG BASE · CAPSULE · ORAL

Approval history

2002-08-22OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →